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Abstract
Spontaneous and glucocorticoid (fluocinolone acetonide, FA)-induced apoptosis of primary mouse thymocytes was
inhibited by protein kinase C (PKC) activators such as bryostatin-1 and phorbol ester 12-O-tetradecanoyl-phorbol-13 acetate
(TPA) within the first 2^4 h of incubation but was enhanced upon prolonged treatment. Only the anti-apoptotic but not the
pro-apoptotic effect of TPA was completely suppressed by the PKC inhibitor Goe 6983 and moderately inhibited by Goe
6976. Immunoblot analysis revealed distinct PKC K, L, N, R, a, W and j signals, a very faint PKCO and no PKCQ signal. Upon
prolonged TPA treatment all PKC isoenzymes became downregulated, albeit at different rates (PKCNsKsWs L,aER,j).
No significant generation of caspase-derived catalytic PKC fragments, as found to be produced upon induction of apoptosis
and to be pro-apoptotic in other systems, was observed in FA- or TPA-treated thymocytes. It is concluded that the early anti-
apoptotic effect of TPA depends on the activation of n-type PKC isoenzymes, whereas stimulation of spontaneous and FA-
induced apoptosis by TPA ensues, at least partially, from a downregulation (or inactivation) of anti-apoptotic PKC species,
i.e. in primary thymocytes PKC activation is primarily involved in a negative regulation of apoptosis. ß 2000 Elsevier
Science B.V. All rights reserved.
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1. Introduction
A large body of evidence indicates a role of pro-
tein kinase C (PKC) isoenzymes in the induction and
regulation of apoptosis (for reviews see [1^3]). For a
long time PKC was considered to exert mainly an
anti-apoptotic e¡ect. This conclusion was predomi-
nantly based on experiments showing PKC inhibitors
to induce and PKC activators (such as phorbol esters
and bryostatin) to inhibit apoptosis. However, other
results are in contrast to these observations, since
they indicate a pro-apoptotic e¡ect of PKC activa-
tion. Recently, apoptosis of certain cell lines was
found to correlate with partial proteolytic degrada-
tion of distinct PKC isoforms [3^9]. In some cases
the constitutively active PKC fragment thus obtained
induced apoptosis upon transfection of HeLa- and
220-8 cells. In apoptotic LNCaP prostate cancer
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cells, however, no partial degradation or PKCN was
observed [10]. Instead, non-degraded PKCN was
found to mediate apoptosis in these cells.
Most of these studies were carried out using estab-
lished or transformed cell lines thus leaving the ques-
tion of the physiological relevance of the results
open. On the other hand, apoptosis of primary cells
has also been reported to be in£uenced by PKC ac-
tivation in either a positive or a negative manner.
The presently best studied example is provided by
primary thymocytes, a classical model of apoptosis
research, in particular of glucocorticoid-induced cell
death [11]. As far as an involvement of PKC in thy-
mocyte apoptosis is concerned, con£icting results
have been published. Thus, several groups reported
on a pro-apoptotic e¡ect of phorbol esters and other
PKC activators (see, for instance, [12^15]) and an
anti-apoptotic e¡ect of kinase inhibitors, whereas
other groups arrived at just the opposite results (re-
viewed in [16]). The interpretation of such observa-
tions is hampered by the fact that phorbol esters not
only activate PKC but, upon prolonged application,
also downregulate PKC along proteolytic pathways.
Therefore, it may critically depend on the experimen-
tal conditions whether a pro-apoptotic or an anti-
apoptotic e¡ect is observed. Another obstacle is the
multiplicity of the mammalian PKC family which is
grouped into three subfamilies, i.e. Ca2- and 12-O-
tetradecanoyl-phorbol-13 acetate (TPA)/diacylglycer-
ol (DAG)-sensitive cPKCs (PKCK, LI, LII and Q),
TPA/DAG-sensitive nPKCs (PKCN, O, R, a and the
more distantly related PKCW/PKD), and TPA/DAG-
insensitive aPKCs (PKCV and j). Upon activation,
some PKC species may inhibit while others may pro-
mote apoptosis.
This con£icting situation prompted us to study the
kinetics of the e¡ect of two PKC activators (phorbol
ester TPA and bryostatin-1) on apoptosis and on
downregulation of distinct PKC isoforms in primary
mouse thymocytes in more detail and to address the
question as to whether or not partial PKC degrada-
tion is involved in the induction of apoptosis. We
arrive at the conclusion that in these cells PKC is
primarily involved in a negative regulation of apo-
ptosis.
2. Materials and methods
2.1. Materials
The phorbol ester TPA was kindly supplied by Dr.
E. Hecker (DKFZ, Heidelberg, Germany). Bryosta-
tin-1 was a generous gift of Dr. G.R. Petit (State
University of Arizona, Tempe, AZ, USA).
Polyclonal antibodies against PKCL (sc-210),
PKCN (sc-937), PKCQ (sc-211), PKCO (sc-214) and
PKCR (sc-215) were obtained from Santa Cruz Bio-
technology (Heidelberg, Germany), anti-PKCj (Y
9339) from Gibco BRL (Gaithersburg, MD, USA)
(PKCj), and monoclonal antibodies against PKCK
(P16 520), PKCN (P36520), PKCa (P15120) and
PKCW (P26720) from Transduction Laboratories
(Lexington, KY, USA). The PKC inhibitors Goe
6976 and Goe 6983 were obtained from Goedecke
(Freiburg, Germany) and horse-radish peroxidase-
conjugated anti-mouse and anti-rabbit antibodies
from Dianova (Hamburg, Germany). The enhanced
chemiluminescence (ECL) kit was obtained from
Amersham (Brunswick, Germany). Other materials
were purchased from Sigma (Munich, Germany).
2.2. Cells and treatment
Suspensions of thymocytes from female NMRI
mice (age 4^7 weeks) were prepared according to
[17] in RPMI 1640 medium supplemented with 5%
heat-inactivated fetal bovine serum, 20 mM L-gluta-
mine, 100 U/ml penicillin and 100 Wg/ml streptomy-
cin. For the experiments, 107 cells/ml were used. Ad-
ditives were dissolved in acetone (¢nal acetone
concentration in the medium 0.1%) and the cells
were incubated at 37‡C, 5% CO2 and 95% humidity
for the times indicated. Human U937 cells were cul-
tivated in RPMI 1640 medium containing 10% fetal
calf serum as described in [9].
2.3. Activity assay and immunoblotting of PKC
TPA-stimulated PKC activity was determined
in Triton X-100 extracts from 1.2U107 thymocytes/
1.5 ml extraction bu¡er [17], according to [18].
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To discriminate PKC-catalyzed from non-PKC-
catalyzed protein phosphorylation, phosphorylation
assays without TPA/phosphatidyl serine were per-
formed, the results of which were subtracted from
the results obtained in the presence of the PKC acti-
vators. Extraction, electrophoretic separation and
immunoblotting of PKC isoenzymes were carried
out as described in [18]. The antibodies were diluted
with phosphate-bu¡ered saline (PBS) containing 1%
bovine serum albumin and 0.05% Tween 20 either
1:500 (polyclonal) or 1:1000 (monoclonal).
2.4. Fluorescence-activated cell scanning (FACS)
analysis of fragmented DNA
Cells were centrifuged for 10 min at 800 rpm, re-
suspended in 1 ml PBS without Ca2 and Mg2 and
precipitated in 14 ml ice-cold ethanol. After a mini-
mum of 12 h at 4‡C the cell pellet was centrifuged.
After DNA staining with DAPI and protein counter-
staining with SR101, FACS analysis was carried out
following a protocol of Sto«hr et al. [19].
2.5. Electrophoretic analysis of fragmented DNA
[20]
1^2U106 cells were centrifuged at 1000 rpm for
10 min, washed with PBS and incubated with lysis
bu¡er (10 mM Tris/HCl, 1 mM EDTA, 0.2% Triton
X-100, pH 7.5) at 0‡C for 30 min. After centrifuga-
tion (13 000 rpm, 4‡C, 10 min, Eppendorf centrifuge)
the supernatant was mixed with the same volume of
ice-cold isopropanol, 2^5 Wl glycogen (1 mg/ml
water) and LiCl (¢nal concentration 1 M). The mix-
ture was stored at 320‡C for at least 1 h. Then the
DNA was isolated by centrifugation (13 000 rpm,
15 min), washed twice with ice-cold ethanol and dis-
solved in 10 mM Tris/boric acid, pH 7.4, containing
1 mM EDTA. Electrophoresis in a 1.4% agarose gel
was carried out as described by Sellins and Cohen
[20]. The gels were stained with 1% ethidium bromide
and photographed under UV light (254 nm).
3. Results and discussion
When immature thymocytes from female NMRI
mice (age 4^7 weeks) were incubated with RPMI-
1640 medium/5% fetal bovine serum, FACS analysis
or agarose gel electrophoresis (Fig. 1) revealed a
time-dependent increase of apoptotic DNA fragmen-
tation which, depending on the cell preparation,
reached values between 10 and 40% within 18 h.
(Fig. 2). This spontaneous apoptosis was strongly
increased by the synthetic glucocorticoid £uocino-
lone acetonide (FA, ED50 = 0.5 nM). PKC activators
such as the phorbol ester tumor promoter TPA and
bryostatin-1 exhibited a biphasic e¡ect, i.e. both
spontaneous as well as FA-induced DNA fragmen-
tation were suppressed within the ¢rst 2^4 h and
synergistically enhanced upon prolonged incubation
(ED50 = 0.5 nM, for both agents). Cell death as de-
termined by the trypan blue exclusion assay followed
FA- or TPA-induced DNA fragmentation with a de-
lay of approximately 4 h (not shown). We did not
¢nd a long-term (s 18 h) anti-apoptotic phorbol es-
ter e¡ect as reported by others [16] even under ex-
actly the same experimental conditions. To restrict
the PKC isoforms mediating the e¡ects of TPA
and bryostatin, experiments with the bisindolylmale-
imide Goe 6983 and the indolcarbazole Goe 6976
were carried out. These potent and rather speci¢c
PKC inhibitors have become valuable research tools
since they allow discrimination, up to a certain de-
gree, between subgroups of PKC isozymes [22^25].
As summarized in Table 1, Goe 6983 is a strong
inhibitor of all PKC isoforms tested so far, with
the exception of PKCW, which is not inhibited. In
contrast, Goe 6976 strongly inhibits both PKCW
and cPKCs but is only a rather poor inhibitor of
a- and nPKCs.
The initial inhibition of apoptosis by TPA was
completely reversed by Goe 6983 indicating that
this e¡ect was due to an activation of PKC with
the exception of PKCW (Fig. 3). As compared with
Goe 6983 the agent Goe 6976 was considerably less
e¡ective in this respect. Thus, the inhibitor experi-
ments argue against an involvement of cPKC species
or PKCW. Instead they indicate nPKC to mediate the
anti-apoptotic e¡ect of the phorbol ester. The mech-
anism of this anti-apoptotic e¡ect is unknown, at
least as primary thymocytes are concerned. Recently,
a study on T cell lines [26] has indicated an activa-
tion of a MAP kinase-dependent signaling pathway
and an impairment of CD95 receptor activation to
be involved.
BBAMCR 14653 11-9-00
J. Rennecke et al. / Biochimica et Biophysica Acta 1497 (2000) 289^296 291
When applied together with TPA (not shown) or
4 h later (Fig. 3) both Goe-type inhibitors failed to
suppress the stimulation of apoptosis by TPA as
measured after 8 or 18 h or by FA as measured after
8 h (not shown). Moreover, ‘spontaneous’ DNA
fragmentation as measured in acetone-treated control
cultures after 18 h was not inhibited but stimulated
by the Goe-substances by about 50%. These results
clearly indicate that only the early anti-apoptotic but
not the delayed pro-apoptotic e¡ect of TPA was
mediated by PKC and that an activation of PKC
was not involved in the induction of spontaneous
and FA-induced apoptosis either. They, moreover,
suggest that the pro-apoptotic e¡ect of TPA was
simply due to TPA-induced downregulation of anti-
apoptotic PKC species.
As shown in Fig. 4, TPA-dependent PKC activity
was indeed strongly downregulated in cell-free prep-
Fig. 1. Demonstration of thymocyte apoptosis by FACS analysis (diagram) and DNA electrophoresis (photograph). For FACS analy-
sis 105 cells each were incubated with 5 nM each of FA, TPA, FA+TPA or acetone (0.1%, control) for 18 h. For DNA electrophore-
sis 1.25U106 cells each were incubated with 10 nM each of FA or TPA for the times indicated. The DNA was extracted, separated
by agarose gel electrophoresis and stained by ethidium bromide. The left slot shows a 1 kb DNA ladder as a reference.
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arations from thymocytes treated with TPA or FA
for 10^20 h whereby both agents acted in a syner-
gistic manner. Immunoblot analysis revealed PKCK,
L, N, R, W, a and j, but not PKCQ, to be expressed in
mouse thymocytes (Fig. 5). This result con¢rms and
extends earlier observations [27^29] whereas, in con-
trast to another report [30], only a very faint immune
signal for PKCO was observed (not shown). Recently,
we also found PKCV in thymocytes (unpublished
results). Upon TPA or FA treatment the immune
signals of all PKC species became downregulated,
however at quite di¡erent kinetics (Fig. 5). At the
timepoint when the anti-apoptotic e¡ect of TPA (or
bryostatin-1) had vanished, i.e. after 4 h in the ab-
sence and 2 h in the presence of glucocorticoid, only
the immune signals of PKCR and j were found not
to be diminished, whereas the signals of the other
PKC species were already clearly reduced. These dif-
ferences in the degradation kinetics of the individual
PKC isoenzymes widely invalidate the argument,
that PKC downregulation preceding apoptosis could
Fig. 4. Treatment of mouse thymocytes with FA and TPA: ef-
fect on TPA-dependent PKC activity in cell extracts. Cells were
cultivated in the presence of FA (10 nM, dotted line), TPA (10
nM, solid line, open circles) or TPA plus FA (solid line, black
dots) for the times indicated. PKC activity was assayed with
histone III S as a substrate and cell extract containing 50 Wg
protein. The assay was carried out in the presence of phospha-
tidyl serine and TPA according to [22], 100% = 230 cpm/Wg pro-
tein. N = 3 ( þ S.D.).
Fig. 3. E¡ect of the PKC inhibitors Goe 6976 and Goe 6983
on the anti-apoptotic (left) and pro-apoptotic (right) e¡ect of
TPA on primary thymocytes. Cells were grown as described for
Fig. 2 for 2 h (left diagram) or 10 h (right diagram). The inhib-
itors (1 WM) were applied simultaneously with acetone/TPA
(left diagram) or 4 h later (right diagram). DNA fragmentation
was determined by FACS analysis. N = 3 ( þ S.D.). C, controls
without inhibitor.
Table 1
Inhibition of PKC isoenzymes by the bisindolylmaleimide Goe
6983 and the indolcarbazole Goe 6976
PKC Goe 6983 Goe 6976
K (rec) 7a 2a
L (rec) 7a 6a
Q (rec) 6a n.d.
cPKC (n) 10b 5b
N (rec) 100b s 20.000c
N (n) 10a 2.000b
O (rec) 10e s 10.000e
R (rec) 25e 700d
R (n) n.d. 250d
j (rec) 60a s 20.000c
W (n) s 20.000a 20a
IC50-values (in WM) as determined with native (n) or recombi-
nant (rec) enzymes in a cell-free system are shown. No data are
available for PKCa. n.d. = not determined.
aData from [22] (substrate: syntide 2).
bData from [23] (substrate: histone III S).
cData from [25] (substrate: histone H 1).
dData from [24] (substrate: myelin basic protein).
eUnpublished data (substrate: histone III S).
Fig. 2. E¡ect of PKC activators on spontaneous (A) and FA-
induced (B) apoptotic DNA fragmentation in mouse thymo-
cytes as determined by FACS analysis. Cells were cultivated for
the times indicated in the absence (A) or presence (B) of 10
nM FA together with acetone (¢nal concentration 0.1%, a), or
acetonic solutions of TPA (b), or bryostatin (R, broken line)
were added (10 nM each). N = 3, for standard deviations see
Fig. 3. Similar results were obtained when DNA fragmentation
was analyzed by agarose gel electrophoresis [21].
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Fig. 5. Immunoblots showing the e¡ects of FA and TPA on the expression of PKC isoenzymes in mouse thymocytes. Thymocytes
were prepared and treated as described for Fig. 2. At the times indicated the proteins from 4W107 cells each were extracted and sepa-
rated by means of 7% sodium dodecyl sulfate^polyacrylamide gel electrophoresis (160 Wg protein per slot). Western blots were pre-
pared and stained with PKC isoenzyme-speci¢c antibodies. The decrease of the electrophoretic mobilities of PKCa and PKCW seen
upon TPA treatment was most probably due to TPA-induced (auto)phosphorylation [17].
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not be discriminated from downregulation resulting
from apoptosis. In fact, degradation of PKCK and N
clearly preceded the TPA-induced increase of DNA
fragmentation, whereas a substantial downregulation
of PKCR and PKCj coincided with cell death as
demonstrated by the trypan blue exclusion test. In
fact, PKCj and PKCR may be considered as internal
standards of protein degradation occurring as a con-
sequence of apoptosis. We therefore propose that the
degradation of PKC in TPA-treated thymocytes oc-
curs along two pathways, i.e. an early isoenzyme-
speci¢c downregulation induced by TPA, followed
by protein degradation along the apoptotic pathway.
If one tentatively assumes that the enhancement of
apoptosis by TPA mainly is due to a downregulation
of anti-apoptotic n-type PKC species (an alternative
mechanism would be enzyme inactivation through
posttranslational modi¢cation), PKCR and perhaps
also PKCa could be ruled out since they were still
widely present at a time point when the anti-apopto-
tic e¡ect of TPA had been replaced already by the
pro-apoptotic e¡ect (i.e. after 4 h of incubation).
Among the PKCs only PKCN was already strongly
downregulated at this timepoint making it a candi-
date for the role of an anti-apoptotic mediator.
Such a conclusion is, however, in contrast to other
reports indicating an active role of PKCN in the ex-
ecution of apoptosis, as, for instance, in human T
cell lines [31], human colon cancer cells [32], salivary
gland acinar cells [33] and LNCaP prostate cancer
cells [10]. With one exception [10] this pro-apoptotic
e¡ect of PKCN was shown to correlate with a partial
proteolytic cleavage of the enzyme which may be
required for the induction of apoptosis. In fact, in
the human promonocytic cell line U937 the induction
of apoptosis by 1-L-D-ara-binofuranosyl cytosine
(ara-C) was found to yield a caspase-3-derived con-
stitutively active 40 kDa fragment of PKCN which
induced apoptosis upon transfection of HeLa cells
[3^6]. Analogous results were obtained for PKCa
[7]. Moreover, for gamma-irradiated thymocytes the
appearance of a corresponding PKCR fragment was
observed, an overexpression of which also induced
apoptosis in 220-8 cells [8]. These observations have
led to the hypothesis that, depending on the cell type
and the apoptosis-inducing agent, a constitutive acti-
vation of PKC due to partial proteolysis is a critical
event in apoptosis.
Using a C-terminal anti-PKCN antibody (sc-937),
which recognizes the caspase-derived fragment, we
also found an almost complete transformation of
PKCN into a 40 kDa catalytic fragment in U937
cells, starting after 1 h and being complete 6 h after
induction of apoptosis with tumor necrosis factor K
(50 ng/ml) plus cycloheximide (5 Wg/ml). A partial
degradation to a 62 kDa fragment was also found
for PKCW in these cells [9]. However, no signi¢cant
generation of corresponding fragments from PKCN,
R, a or W was observed in mouse thymocytes treated
for 2, 4 and 8 h with TPA as compared to control
cells treated with acetone. Also FA treatment for up
to 8 h did not induce a substantial formation of such
fragments from PKCN, R and a ; only for PKCW was
a distinct signal of a 62 kDa fragment observed.
Beside these immunoblot data the inability of Goe-
type PKC inhibitors to suppress the pro-apoptotic
e¡ect of TPA or FA strongly argues against an in-
volvement of proteolytic PKC fragments in thymo-
cyte apoptosis. These fragments still contain the
ATP-binding site of the catalytic domain and should,
therefore, be inhibited by the Goe type inhibitors. In
fact, using PKCW autophosphorylation as an assay
and Goe 6976 as an inhibitor we measured IC50 val-
ues of 20 WM for the complete enzyme and 2 WM for
the catalytic fragment.
Although our results are apparently at odds with
another report showing a selective inhibitory e¡ect of
Goe 6983 on thymocyte apoptosis induced by the
PKC activator ingenol-3,20-dibenzoate [15], we con-
clude that the induction of apoptosis by the phorbol
ester is at least partially due to a downregulation or
endogenous inactivation of anti-apoptotic PKC spe-
cies. Such a permissive e¡ect is expected to favor
spontaneous apoptosis or the pro-apoptotic e¡ect
of factors in the cell culture medium. Moreover, it
most easily explains that upon prolonged incubation
(s 4 h) FA-induced apoptosis was synergistically en-
hanced by TPA and that spontaneous apoptosis in
control cultures was stimulated by Goe-type inhibi-
tors. However, the stimulatory e¡ect of the inhibitors
was not as strong as that of TPA and seen only upon
prolonged incubation. This may indicate that, in ad-
dition to PKC inactivation, PKC-independent pro-
cesses may participate in the pro-apoptotic e¡ect of
the phorbol ester [34].
Since TPA has become famous as a highly potent
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skin tumor promoter rather than an inducer of thy-
mocyte apoptosis the question arises as to how a
study on thymocytes may contribute to a better
understanding of tumor development. As far as the
tumor-promoting e¡ect of TPA is concerned contra-
dictory hypotheses postulating a key role of either
PKC activation [35] or PKC downregulation [36]
have been put forward. However, no substantial
PKC downregulation was found in the course of
skin tumor promotion, i.e. upon chronic TPA treat-
ment and in neoplastic lesions [37]. This ¢nding
strongly indicates that the tumor-promoting e⁄cacy
of TPA depends on a repeated activation of PKC
which, in analogy to the thymocyte model, may
lead to a suppression of programmed cell death,
whereas PKC downregulation would counteract
such an e¡ect.
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